10-Q · May 13, 2026
Reviva Pharmaceuticals Holdings, Inc. reported a notable improvement in its net loss for Q1 2026, narrowing it to approximately $3.2 million or $0.46 per share, compared to a loss of $6.4 million or $2.61 per share in…
Earnings analysis · 10-Q
RVPH earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include quantitative income-statement, balance-sheet or cash-flow data, but it discloses pervasive material weaknesses in internal controls as of June 30, 2026. Reviva remains dependent…
Read full summary
The supplied 10-Q text does not include quantitative income-statement, balance-sheet or cash-flow data, but it discloses pervasive material weaknesses in internal controls as of June 30, 2026. Reviva remains dependent on the successful development and approval of brilaroxazine, with no approved commercial products and no NDA submitted. The May 2026 Nasdaq delisting and transition to OTCQB create additional liquidity and equity-financing risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Remediation efforts initiated
Management commenced remediation of the disclosed control deficiencies by hiring an additional internal accounting resource and engaging a third-party consulting firm for IT general controls. The filing also describes continued personnel realignment to strengthen management review and documentation.
-
Financial statements deemed fairly presented
The company states that its unaudited condensed consolidated financial statements fairly present its financial position, results of operations and cash flows in all material respects and conform to U.S. GAAP.
-
No unregistered equity sales
The company reported no unregistered sales of equity securities during the quarter ended June 30, 2026.
-
No insider trading arrangements
No officers or directors adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter ended June 30, 2026.
What to watch
-
Pervasive material weaknesses
As of June 30, 2026, management concluded that disclosure controls and procedures were ineffective. The company identified pervasive material weaknesses in its control environment, IT general controls and process-level controls affecting substantially all account balances and disclosures.
-
Dependence on unapproved brilaroxazine
The company has no products approved for commercial sale and states that its business depends heavily on brilaroxazine, its only advanced product candidate. The company has not submitted an NDA and does not expect to be in a position to do so for the foreseeable future, pending additional development activities including the planned bioequivalence study and RECOVER-2 trial.
-
Nasdaq delisting and financing risk
The company received a Nasdaq delisting determination on May 12, 2026, was suspended from Nasdaq trading on May 14, 2026, and is now quoted on the OTCQB Venture Market. Management states the delisting may reduce liquidity and market price, limit investors and impair the company’s ability to raise equity financing.
-
OTCQB liquidity and compliance risk
The company states that OTC Markets trading is often thin, sporadic and volatile, with wide price fluctuations, and warns that failure to comply with OTCQB continuing listing requirements could result in delisting. The filing also notes that the common stock may fall within the definition of a penny stock.
-
Potential additional clinical trials
The company identifies potential regulatory and clinical execution risks, including the possibility that the FDA may require additional Phase 3 trials. Such a requirement would increase costs and prolong development of brilaroxazine.
Management's outlook
No quantitative financial guidance is provided in the supplied 10-Q text. The filing discusses operational development timing but does not provide revenue or EPS targets.
Earlier filings 4
10-K · March 30, 2026
Reviva Pharmaceuticals (RVPH) is a late‑stage biopharma focused on brilaroxazine (RP5063) with completed toxicology and a positive Phase 2 acute schizophrenia study (N = 234) where the 15 mg (p = 0.0212) and 50 mg (p =…
10-Q · November 13, 2025
Reviva reported a smaller net loss of $4,010,773 for 2025Q3 versus $8,365,798 in 2024Q3, driven by a decline in operating expenses (total operating expenses fell to $4,029,841 from $8,462,534). Cash and cash equivalents…
10-Q · August 14, 2025
Reviva reported a net loss of $6,053,610, or $(0.12) per share, for the quarter ended June 30, 2025, an improvement versus the prior-year quarter net loss of $7,859,919, or $(0.26) per share. Total operating expenses…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.